{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"VYNE","limit":50},"count":50,"signals":[{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":76,"context":"cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop our current and future product candidates may have a material adverse impact on it. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in derivation, interference or other p","filed_date":"2026-02-27","accession":"0001566044-26-000002","full_text":"https://origin.rootz.global/static/filing/0001566044-26-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"ski is qualified to serve on our Board given his leadership position with our company, and his extensive experience in operating and leadership roles in the pharmaceutical industry. Tyler Zeronda was appointed as our Chief Financial Officer and Treasurer in March 2022 and previously served as our Interim Chief Financial Officer and Treasurer since June 2021. Mr. Zeronda previously served as Vice President of Finance of the Company from","filed_date":"2026-02-27","accession":"0001566044-26-000002","full_text":"https://origin.rootz.global/static/filing/0001566044-26-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":65,"context":"cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop our current and future product candidates may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in derivation, interference or other p","filed_date":"2025-03-06","accession":"0001628280-25-010908","full_text":"https://origin.rootz.global/static/filing/0001628280-25-010908.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"ified to serve on our Board given his leadership position with our company and Foamix, and his extensive experience in operating and leadership roles in the pharmaceutical industry. Tyler Zeronda was appointed as our Chief Financial Officer and Treasurer in March 2022 and previously served as our Interim Chief Financial Officer and Treasurer beginning in June 2021. Mr. Zeronda has been responsible for all finance activities related to o","filed_date":"2025-03-06","accession":"0001628280-25-010908","full_text":"https://origin.rootz.global/static/filing/0001628280-25-010908.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":66,"context":"or failure to obtain a license to proprietary rights that we may  13 [Table of Contents](#i06a15c5c75f64f5eb4069622f8c01ef9_7) require to develop our current and future product candidates may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in derivation, interference or other p","filed_date":"2024-03-01","accession":"0001628280-24-008178","full_text":"https://origin.rootz.global/static/filing/0001628280-24-008178.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":11,"context":"ified to serve on our Board given his leadership position with our company and Foamix, and his extensive experience in operating and leadership roles in the pharmaceutical industry. Tyler Zeronda was appointed as our Chief Financial Officer and Treasurer in March 2022 and previously served as our Interim Chief Financial Officer and Treasurer beginning in June 2021. Mr. Zeronda joined Foamix in April 2019, and from the closing of the Mer","filed_date":"2024-03-01","accession":"0001628280-24-008178","full_text":"https://origin.rootz.global/static/filing/0001628280-24-008178.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"osition with the Company and Foamix, and his extensive experience in operating and leadership roles in the pharmaceutical industry.  Patrick LePore has served on our Board since September2020 and was appointed as the lead independent director in February2021. Mr.LePore previously served as Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies, Inc. from September2006 until its sale to affiliates of TPG Capital in","filed_date":"2023-11-13","accession":"0001104659-23-117180","full_text":"https://origin.rootz.global/static/filing/0001104659-23-117180.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop our current and future product candidates may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in derivation, interference or other p","filed_date":"2023-03-14","accession":"0001628280-23-007900","full_text":"https://origin.rootz.global/static/filing/0001628280-23-007900.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"ified to serve on our Board given his leadership position with the Company and Foamix, and his extensive experience in operating and leadership roles in the pharmaceutical industry. Tyler Zeronda was appointed as the Companys Chief Financial Officer and Treasurer in March 2022 and previously served as Interim Chief Financial Officer and Treasurer since June 2021. Mr. Zeronda previously served as Vice President of Finance of the","filed_date":"2023-03-14","accession":"0001628280-23-007900","full_text":"https://origin.rootz.global/static/filing/0001628280-23-007900.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"ions, and there is substantial doubt about our ability to continue as a going concern. We could also be forced to delay, reduce or terminate our research and development activities which would have a material adverse effect on our financial condition; Risks and uncertainties related to the development of new chemical entities; We may encounter delays in enrolling patients and successfully completing clinical trials for","filed_date":"2022-03-17","accession":"0001628280-22-006545","full_text":"https://origin.rootz.global/static/filing/0001628280-22-006545.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"a 4% prepayment fee and accrued but unpaid interest. Following the prepayment, the Amended and Restated Credit Agreement and the security interests thereunder were terminated.  On August 12, 2021, we announced a licensing arrangement with In4Derm, giving us access to their library of novel BET inhibitor compounds.  On August 12, 2021, we announced that we initiated a process to explore a sale or license of our topical minocycline","filed_date":"2022-03-17","accession":"0001628280-22-006545","full_text":"https://origin.rootz.global/static/filing/0001628280-22-006545.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"mpany with the SEC pursuant to Rule 424(b)(5) under the Securities Act and in accordance with Section 5(a) hereof, together with all documents and information incorporated therein by reference. (bb)  Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries (a","filed_date":"2022-03-15","accession":"0001104659-22-033991","full_text":"https://origin.rootz.global/static/filing/0001104659-22-033991.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"of property or the conduct of its businesses requires such qualification, except where the failure to be so qualified or in good standing could not, in the aggregate, reasonably be expected to have a material adverse effect on the condition (financial or otherwise), results of operations, shareholders equity, properties, business or prospects of the Company and its Subsidiaries taken as a whole (a **Material Adverse Eff","filed_date":"2021-08-12","accession":"0001104659-21-104266","full_text":"https://origin.rootz.global/static/filing/0001104659-21-104266.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":5,"context":"ctitioners who diagnose and manage dermatologic conditions. We also have a centralized marketing, market access, supply chain and distribution infrastructure.  For the year ended December 31, 2020, a significant percentage of our sales were to three national wholesale drug distributors. In the fourth quarter of 2020, we expanded our distribution capabilities with respect to AMZEEQ and ZILXI. In addition to distributing our products","filed_date":"2021-03-04","accession":"0001566044-21-000010","full_text":"https://origin.rootz.global/static/filing/0001566044-21-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"e certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our current and future drugs may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or other proceedings i","filed_date":"2021-03-04","accession":"0001566044-21-000010","full_text":"https://origin.rootz.global/static/filing/0001566044-21-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":24,"context":"ghts shall have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Per Share Purchase Price equals $2.37, subject to adju","filed_date":"2021-01-28","accession":"0001104659-21-008768","full_text":"https://origin.rootz.global/static/filing/0001104659-21-008768.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"n specialty pharmaceuticals, provides valuable insight of the pharmaceutical industry to the Board and to the Company.  THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR  THE ELECTION OF EACH OF THE ABOVE NAMED NOMINEES  Director Continuing in Office Until the 2021 Annual Meeting of Stockholders  David Domzalski is the Companys President and Chief Executive Officer and also serves as a director. From July2017 until the Closin","filed_date":"2020-06-22","accession":"0001104659-20-075684","full_text":"https://origin.rootz.global/static/filing/0001104659-20-075684.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"of property or the conduct of its businesses requires such qualification, except where the failure to be so qualified or in good standing could not, in the aggregate, reasonably be expected to have a material adverse effect on the condition (financial or otherwise), results of operations, shareholders equity, properties, business or prospects of the Company and its subsidiaries taken as a whole (a **Material Adverse Eff","filed_date":"2020-06-09","accession":"0001104659-20-071403","full_text":"https://origin.rootz.global/static/filing/0001104659-20-071403.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"o legal proceedings and claims arising in connection with its business. As of March 31, 2020, no claims or actions pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company. 29 *IPO Lawsuits* On November 8, 2018 and January 28, 2019, two purported class actions were filed in the Superior Court of California, San Mateo County, against the Company and certa","filed_date":"2020-05-11","accession":"0001104659-20-059152","full_text":"https://origin.rootz.global/static/filing/0001104659-20-059152.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"are conducting two Phase 3 clinical trials (one in the U.S. and one in Europe) to evaluate serlopitant as a treatment for pruritus associated with prurigo nodularis. In October 2019, we completed enrollment in both trials with 285 patients enrolled in the U.S. trial and 295 patients enrolled in the European trial. We expect to report top-line data from these PN Phase 3 trials in March or April of 202","filed_date":"2020-03-03","accession":"0001564590-20-008442","full_text":"https://origin.rootz.global/static/filing/0001564590-20-008442.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"nses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the Uni","filed_date":"2020-03-03","accession":"0001564590-20-008442","full_text":"https://origin.rootz.global/static/filing/0001564590-20-008442.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"verage award date fair value of $4.08 per share and vests over 2 years. 33,400 restricted stock units were cancelled during the year and vesting of 423,490 restricted stock units held by the Companys named executive officers were accelerated in full on December 11, 2019 in connection with the pending Merger in order to mitigate potential negative tax consequences  100 to both the Company and the named executive officer","filed_date":"2020-03-03","accession":"0001564590-20-008442","full_text":"https://origin.rootz.global/static/filing/0001564590-20-008442.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"&#x2022; |  We are conducting two Phase 3 clinical trials (one in the U.S. and one in Europe) to evaluate serlopitant as a treatment for pruritus associated with PN. In October 2019, we completed enrollment in both trials with 285 patients enrolled in the U.S. trial and 295 patients enrolled in the European trial. We expect to report top-line data from these PN Phase 3 trials in March or April of 202","filed_date":"2019-10-31","accession":"0001564590-19-039188","full_text":"https://origin.rootz.global/static/filing/0001564590-19-039188.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"ility for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company. 8.Stockholders Equity Equity Incentive Plans Under the Companys 2011 Stock Incentive Plan (the 2011 Plan), the Company","filed_date":"2019-10-31","accession":"0001564590-19-039188","full_text":"https://origin.rootz.global/static/filing/0001564590-19-039188.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"and Drug Administration or FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict w","filed_date":"2019-08-01","accession":"0001564590-19-027984","full_text":"https://origin.rootz.global/static/filing/0001564590-19-027984.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ility for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company. 8.Stockholders Equity Equity Incentive Plans Under the Companys 2011 Stock Incentive Plan (the 2011 Plan), the Company","filed_date":"2019-08-01","accession":"0001564590-19-027984","full_text":"https://origin.rootz.global/static/filing/0001564590-19-027984.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":33,"context":"s: |  |  &#x2022; |  Initial Equity Grants. Each non-employee director who joins the board receives an option to purchase shares of our common stock, subject to the option vesting in three equal installments on each anniversary of the directors service and subject to continued service, as follows: if our stock price is less than or equal to $8.00 per share on the date of grant, the director receives","filed_date":"2019-05-10","accession":"0001564590-19-018528","full_text":"https://origin.rootz.global/static/filing/0001564590-19-018528.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"|  (1) |  Member of the Audit Committee. | | |  (2) |  Member of the Compensation Committee. | | |  (3) |  Member of the Nominating and Corporate Governance Committee. | | |  (4) |  Ms. Sandoval was appointed as a Class I director in March 2019, simultaneous with the resignation of Dr. Albert Cha as a Class I member of our board of directors. | | Set forth below is biographical information for the nominees and each person whos","filed_date":"2019-05-10","accession":"0001564590-19-018528","full_text":"https://origin.rootz.global/static/filing/0001564590-19-018528.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"and Drug Administration or FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict w","filed_date":"2019-05-02","accession":"0001564590-19-015358","full_text":"https://origin.rootz.global/static/filing/0001564590-19-015358.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ility for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company. 8.Stockholders Equity Equity Incentive Plans Under the Companys 2011 Stock Incentive Plan (the 2011 Plan), the Company","filed_date":"2019-05-02","accession":"0001564590-19-015358","full_text":"https://origin.rootz.global/static/filing/0001564590-19-015358.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":50,"context":"2019. This trial is being conducted at approximately 40 sites in the United States and is expected to enroll approximately 200 patients who have experienced CPUO for at least six months prior to enrollment. This trial includes a ten-week treatment period and a five-week follow-up period. This trial is intended to evaluate if treatment with 5 mg serlopitant daily for ten weeks can reduce CPUO compare","filed_date":"2019-02-28","accession":"0001564590-19-005451","full_text":"https://origin.rootz.global/static/filing/0001564590-19-005451.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"nses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the Uni","filed_date":"2019-02-28","accession":"0001564590-19-005451","full_text":"https://origin.rootz.global/static/filing/0001564590-19-005451.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"and Drug Administration or FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict w","filed_date":"2018-11-07","accession":"0001564590-18-028098","full_text":"https://origin.rootz.global/static/filing/0001564590-18-028098.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ility for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company. 8.Stockholders Equity (Deficit) Equity incentive plan Under the Companys 2011 Stock Incentive Plan (the 2011 Plan), the","filed_date":"2018-11-07","accession":"0001564590-18-028098","full_text":"https://origin.rootz.global/static/filing/0001564590-18-028098.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ility for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company. 14 8.Stockholders Equity (Deficit) Equity incentive plan Under the Companys 2011 Stock Incentive Plan (the 2011 Plan),","filed_date":"2018-08-01","accession":"0001564590-18-018481","full_text":"https://origin.rootz.global/static/filing/0001564590-18-018481.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"and Drug Administration or FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict w","filed_date":"2018-05-09","accession":"0001628280-18-006412","full_text":"https://origin.rootz.global/static/filing/0001628280-18-006412.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ility for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not currently aware of any matters that could have a material adverse effect on the financial position, results of operations, or cash flows of the Company. 8.Stockholders Equity (Deficit) Equity incentive plan Under the Companys 2011 Stock Incentive Plan (the 2011 Plan), the","filed_date":"2018-05-09","accession":"0001628280-18-006412","full_text":"https://origin.rootz.global/static/filing/0001628280-18-006412.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"day wellbeing. Pruritus can lead to trouble sleeping, resulting in loss of work productivity and increased anxiety and depression as patients struggle to maintain selfcontrol. Chronic pruritus is a hallmark of many dermatologic and systemic diseases, such as atopic dermatitis, psoriasis and prurigo nodularis, and is the predominant reason that patients with these diseases experience so much discomfor","filed_date":"2018-03-28","accession":"0001628280-18-003726","full_text":"https://origin.rootz.global/static/filing/0001628280-18-003726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"nses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the Uni","filed_date":"2018-03-28","accession":"0001628280-18-003726","full_text":"https://origin.rootz.global/static/filing/0001628280-18-003726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"e negotiation and may vary significantly among different CROs and trial sites; | | | | | | | | the number of subjects required for clinical trials of serlopitant may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for posttreatment followup at a higher rate than we anticipate; |","filed_date":"2018-01-23","accession":"0001628280-18-000542","full_text":"https://origin.rootz.global/static/filing/0001628280-18-000542.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"and Analysis of Financial Condition and Results of Operations, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such an event, the market price of our common stock could decline, and you may lose all or part of your inve","filed_date":"2018-01-23","accession":"0001628280-18-000542","full_text":"https://origin.rootz.global/static/filing/0001628280-18-000542.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":26,"context":"e negotiation and may vary significantly among different CROs and trial sites; | | | | | | | | the number of subjects required for clinical trials of serlopitant may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for posttreatment followup at a higher rate than we anticipate; |","filed_date":"2017-12-28","accession":"0001628280-17-012730","full_text":"https://origin.rootz.global/static/filing/0001628280-17-012730.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"and Analysis of Financial Condition and Results of Operations, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such an event, the market price of our common stock could decline, and you may lose all or part of your inve","filed_date":"2017-12-28","accession":"0001628280-17-012730","full_text":"https://origin.rootz.global/static/filing/0001628280-17-012730.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":36,"context":"roceedings and claims arising in connection with its business. As of June30, 2026, there were no claims or actions pending against the Company that, in the opinion of management, are likely to have a material adverse effect on the Company.NOTE 11 - SEGMENT INFORMATIONAs of June30, 2026, VYNE operated in one operating segment, and therefore one reportable segment, focused on the development of differentiated therapies to","filed_date":"2026-08-13","accession":"0001566044-26-000010","full_text":"https://origin.rootz.global/static/filing/0001566044-26-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"purposes of clauses (i) and (iii) above, any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect (as defined below). As used herein, **Governmental Authority** means (i) any federal, provincial, state, local, municipal, national or international government or governmental authority, regulatory o","filed_date":"2026-09-14","accession":"0001104659-26-107485","full_text":"https://origin.rootz.global/static/filing/0001104659-26-107485.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"Foamix, and his extensive experience in operating and leadership roles in the pharmaceutical industry.  10 [TABLE OF CONTENTS](#TOC) Patrick LePore has served on our Board since September2020 and was appointed as the lead independent director in February2021. Mr.LePore previously served as Chairman, Chief Executive Officer and President of Par Pharmaceutical Companies, Inc. from September2006 until its sale to affiliates of TPG Capital in","filed_date":"2022-06-17","accession":"0001104659-22-072470","full_text":"https://origin.rootz.global/static/filing/0001104659-22-072470.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"|  |  28 |  |  |  | |  |  Summary Compensation Table |  |  |  |  |  28 |  |  |  | |  |  Outstanding Equity Awards at Fiscal Year End |  |  |  |  |  29 |  |  |  | |  |  Compensation Arrangements with Named Executive Officers |  |  |  |  |  30 |  |  |  | |  |  INFORMATION ABOUT STOCK OWNERSHIP |  |  |  |  |  34 |  |  |  | |  |  DELINQUENT SECTION 16(a) REPORTS |  |  |  |  |  37 |  |  |  | |  |  ADDITIONAL INFORMATION |","filed_date":"2021-06-07","accession":"0001104659-21-077700","full_text":"https://origin.rootz.global/static/filing/0001104659-21-077700.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"and Drug Administration or FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict w","filed_date":"2018-08-01","accession":"0001564590-18-018481","full_text":"https://origin.rootz.global/static/filing/0001564590-18-018481.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"lenges and amendments to certain aspects of the ACA. For example, on July 4, 2025, the One Big Beautiful Bill Act (\"OBBBA\"), was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans wi","filed_date":"2026-02-27","accession":"0001566044-26-000002","full_text":"https://origin.rootz.global/static/filing/0001566044-26-000002.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VYNE","company":"VYNE Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"e NSV. The primary efficacy endpoint of the trial is an evaluation of the proportion of subjects achieving F-VASI50 at Week 24 compared to vehicle. In January 2025, we announced the completion of enrollment in the trial. We anticipate top-line results from the 24-week double-blind portion of the trial to be available in mid-2025. Preclinical Studies for Multiple Indications Vitiligo We conducted a pr","filed_date":"2025-03-06","accession":"0001628280-25-010908","full_text":"https://origin.rootz.global/static/filing/0001628280-25-010908.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"6f3239c60f901c092ad3260b1a743d37eef1a4355d41d011662e166a19c7b57e","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"2afdc58281b8227f127612025927f15ea8f6d9dbecfdbe6b5f035af96b20a6ea","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":96,"hourly_limit":500,"remaining":404,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}